RE:RE:RE:RE:RE:RE:RE:ASCO relevanceBack to the original discussion of share price. Forgetting about AA, one P3 ready trial is worth 1bln+. Most contend we have 2. This implies a value of around $30/share US. Regardless of the therapy, a big pharma will likely not buy the panc and Mbc rights for 10bln, which I think they are worth, from the current SP. Therefore, in order to get the 10bln I believe management is looking for, we need a launching point much higher than current levels. Oppenheimer coverage laying out our story could get us to 30 - From which big pharma could reasonably make an offer for 10bln. I believe with bracelet and ind 213, a big pharma partner could gain AA with a confirmatory P3 required. This would immediately validate and justify the price they shelled out for us. These are just my views. They may have no relevance to what actually happens.